AstraZeneca offloads former crown jewel Crestor as it continues to refocus on oncology drugs
This is the way Crestor ends. Not with a bang, but a whimper.
AstraZeneca is selling off European rights for the once mighty megablockbuster to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
